Services are coordinated by the CIS Co-Directors, Drs. Becich and Chandran. and are described in the text that follows. The CIS facilitates quality controlled collection of clinical information via a variety of information systems managed by Dr. Becich and his team. These clinical information systems which feed data to the research information systems ofthe CIS include the Clinical Trials Management Application (CTMA), the Pathology Laboratory Systems (Corner's CoPath Plus for anatomic pathology and Misys'Flexilab for clinical pathology), the Immunologic Monitoring and Cellular Products Laboratories (IMCPL), the Registry Research Information Service (ImPath), and three electronic medical records systems [the Medical Archival System (MARS, Inc.), Corner's PowerChart and Epic's EpicCare System]. These seven clinical systems (with the exception of ImPath) all use HL7 (Health Level 7, see www.hl7.org/) messaging to pass data to (and in some instances from) our research information systems. The diagram below shows the information flow from our clinical systems to our honest brokers information systems (Cancer Registry &Tissue Banking Systems). The research data that is in highest demand in our current environment comes from four sources: 1) clinical trials, 2) clinical annotation of tissue and serum samples, 3) information management and analysis related to microarray (tissue and cDNA) and proteomic experiments, and 4) clinical abstracts of patient treatment and outcome for translational research. We have built CTMA to serve the complete needs of clinical trials at UPCI. This is a system that manages a clinical trial from protocol proposal to closing of the trial. The functional modules of CTMA are described in the sections that follow. Data from the anatomic pathology Laboratory Information Systems or LIS (CoPath Plus) is entered into Synoptic Templates (structured data entry forms) that were developed by the Pathology Department in collaboration with the surgeons, medical oncologists, and other key UPCI members. These cancer checklists are entered into pathology reports and stored in discrete data elements in the LIS. These data are then stored in our data warehouse and combined with data extracted from the ImPath Cancer Registry. The integrated Cancer Registry has a research information services group that focuses on collecting organ site specific data into the ImPath system from a variety of sources, including our two medical record systems, our Radiology Information Systems, our Radiation Therapy Information System, and chart review in medical oncologists'and surgeons'offices. The Registry Research Information Service (RIS) and the LIS units form the foundation of our Tissue Banking and Pathology Tools. Our tissue banking and pathology tools include the caBIG? program's caTIES and caTISSUE Suite and other systems that were developed for cancer researchers to gain access to de-identified clinical, pathology, and outcomes data to identify cohorts for study. The Oracle data warehouse that is the basis for all of our research applications can also be queried via Discovery Tools (Oracle) to do ad hoc queries to structure data in SPSS and other SQL transforms for use by biostatisticians, cancer researchers, and clinical outcomes researchers. We have a sophisticated set of output tools developed in Crystal Reports (Crystal Decisions;Vancouver, BC) to provide detailed reporting formats. We work collaboratively with the Clinical Research Services and the Biostatistics Facility to provide them with high quality reports and data output to facilitate cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-25
Application #
8519330
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$310,020
Indirect Cost
$69,739
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478

Showing the most recent 10 out of 1187 publications